SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community anticipates further upside, with some eyeing previous highs and staking opportunities. Discussion is centered around potential rallies and the possibility of outperforming other major cryptocurrencies. Talk also highlights treasury strategies and corporate adoption as potential catalysts for growth.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle ($ORCL) is trending due to news of a significant cloud computing deal with OpenAI, sparking both excitement and skepticism within the community. Some investors believe the deal will propel ORCL to new heights, while others question the financial viability and sustainability of OpenAI's involvement and consider the surge a potential bubble. Community members are actively debating the long-term implications of the partnership, with some highlighting potential risks and an insider lock-up ending soon.

Why Queen Kitty ($QKitty) Is The Meme Token You’ve Been Waiting For  Queen Kitty isn’t just another hype project—this is a real movement with substance and community power!  Why hold $QKitty? 😼 Real dev, real builds: No fake teams, no copy-paste code. Everything you see is made from scratch. 💧 Working Faucet: Free QKitty for the community. Want to know how? Just ask! 🏆 Big Buy Competition Bot: See top buyers live, fight for the throne, and win rewards! 🎮 Multi-token P2E game coming soon: Play and earn across Web, iOS, Android! 🐾 NFT collecting soon: Cutest collection in crypto, bringing perks and more ways to earn.  Queen Kitty means innovation, transparency, and real delivery for holders. Curious? Join the chat and ask anything!  $QKitty: By the community, for the community. To the moon, together! 🚀🐱

Queen Kitty

Queen Kitty is trending amid discussions about its upcoming DEX launch in November and a trading bot that generates revenue. The community is also buzzing about a potential airdrop of QKITTY.X and BROKE.X tokens. Some users highlight that the project emphasizes transparency and has a trusted developer.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending due to a special dividend announcement in the form of warrants, sparking debate about its implications. While some community members see this as a catalyst for a potential short squeeze and long-term value, others express concerns about potential dilution and market manipulation. The stock's volatile price action and heavy trading volume are fueling active discussions about its future direction and the impact of the warrant distribution.

Wearable Devices Ltd. engages in the development of a non-invasive neural input technology that allows operation and control of digital devices using subtle finger movements and fingertip pressure. It offers Mudra band, a neutral input wristband. The company was founded by Asher Dahan, Guy Wagner, and Leeor Langer in March 2014 and is headquartered in Yokne'am Illit, Israel.

Wearable Devices Ltd

WLDS is trending due to a recently granted U.S. patent for its gesture and voice-controlled interface technology, sparking discussions about potential applications in AI wearables and possible acquisition by major tech companies like Apple. The community is actively debating the stock's potential for a multi-day run, buyout speculation, and potential short squeeze, while also weighing concerns about possible dilution. Some traders are drawing comparisons to other high-flying stocks.

Klarna Group Plc operates as an investment holding company. It provides an e-commerce payment solutions for merchants and shoppers. The firm connect an array of different financial services and commerce organizations, from PSPs, traditional banks, card networks and open banking providers, to commerce enablers, technology partners, in-store payments providers and shipping and return logistics providers. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna's NYSE debut has traders discussing its valuation relative to competitors like Affirm, with some pointing to its potential for long-term growth in the BNPL sector. Concerns about the company's business model and potential regulatory scrutiny are also circulating. The IPO's initial price action and allocation sizes are driving immediate conversation within the community.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending as investors weigh competitive pressures in the AI cloud space, particularly after Oracle's recent gains, despite positive developments with Netflix and autonomous driving. The community is actively discussing whether recent drops represent a buying opportunity or a sign of further declines, with debates around fair valuation and future growth prospects. Broader market factors and potential impacts from economic data releases are also influencing sentiment.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is trending downwards, driven by an analyst downgrade and concerns over increasing competition from Amazon and Netflix, leading to a significant sell-off. Community sentiment is largely negative, with many investors expressing frustration and questioning the company's leadership and strategic direction. Some investors believe the stock is oversold and ripe for a bounce, while others fear further declines and are considering exiting their positions.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCI is trending as the community discusses its potential, partnerships (Nokia, Oracle), and recent movements relative to the broader tech sector, particularly AI-related stocks. Bullish sentiment is fueled by the anticipation of analyst upgrades and potential short squeezes. Some are also noting attractive valuations relative to future revenue forecasts.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

AVXL is trending due to discussions surrounding its potential Alzheimer's drug and recent clinical data, with community members debating the efficacy and safety profile compared to existing treatments. Some traders are pointing to potential short squeezes and heavy manipulation, while others express concerns about the company's history and await EMA approval. The stock's volatile price movement is fueling speculation about its future.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Texas-based biotechnology company Cassava Sciences, Inc. (SAVA) tumbled 33% on Tuesday after the company reported that its oral drug Simufilam did not yield positive results in patients with mild to moderate Alzheimer’s disease in its second Phase 3 study.The drug showed no treatment benefit for patients in the study called REFOCUS-ALZ, the company said.Cassava added that it would discontinue the Alzheimer’s disease development program with Simufilam by the end of the second quarter of 2025. &nbsp;REFOCUS-ALZ was discontinued on Nov. 25 last year after the company identified that a previous phase 3 study failed to yield positive results.Cassava CEO Rick Barry acknowledged the results were "unambiguous" and added that the company was “disappointed.”“Cassava will discontinue all efforts to develop Simufilam for Alzheimer’s disease, and we expect to phase out the program by the end of Q2 2025,” he said.The CEO added that the company has initiated preclinical studies to gauge the potential of Simufilam in treating TSC-related epilepsy.Company CFO Eric Schoen said the firm continues to be committed to enhancing shareholder value. “Cassava is well-capitalized with approximately $128.6 million in cash and cash equivalents as of Dec. 31, 2024,” he added.Cassava reported a net loss of $27.60 million in the three months ended December 2024 compared to a net loss of $20.92 million in the corresponding quarter of 2023.On Stocktwits, retail sentiment about Cassava Sciences climbed further into the ‘bullish’ territory (60/100), while message volume jumped from ‘normal’ to ‘high’ in the past 24 hours.<figure class="image"><img style="aspect-ratio:650/146;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_25_at_1_50_58_PM_png_d88af5aac9.webp" alt="SAVA’s Sentiment Meter and Message Volume as of 1:50 p.m. ET on March 25, 2025 | Source: Stocktwits" width="650" height="146"><figcaption>SAVA’s Sentiment Meter and Message Volume as of 1:50 p.m. ET on March 25, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expects the share price to drop further in the coming days.<stembedurl>https://stocktwits.com/pg3015/message/609181500</stembedurl>Another user expressed optimism, highlighting the company’s debt-free status.<stembedurl>https://stocktwits.com/mcrotary/message/609180826</stembedurl>SAVA stock has lost over 30% this year and is down by over 90% in the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/merck-enters-license-agreement-with-china-based-hengrui-pharma/ch7yxJsRbdw">Merck Enters $2B License Agreement With China-Based Hengrui Pharma For Heart Disease Drug: Retail’s Unswayed</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

An employee pipettes in a laboratory of a biopharmaceutical company | Photo by Bernd Weißbrod/picture alliance via Getty Images

Cassava Sciences Stock Drops Over 30% After Alzheimer’s Drug Fails Study – But Retail Remains Hopeful

The drug showed no treatment benefit for patients in the study called REFOCUS-ALZ, the company said, while adding that the Alzheimer’s disease development program with Simufilam will be discontinued by the end of the second quarter of 2025. 

Equity

SAVA Deadline Today: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit

SAVA Deadline Today: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit SAVA Deadline Today: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc...

Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA

Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA Cassava Sciences, Inc. Securities Fraud Class...

Lead Plaintiff Deadline on February 10, 2025 for SAVA Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm

Lead Plaintiff Deadline on February 10, 2025 for SAVA Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm Lead Plaintiff Deadline on February 10, 2025...

CASSAVA SCIENCES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA

Kahn Swick & Foti, LLC ('KSF') and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff...

SAVA Deadline: Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between...

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of...

Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to...

Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - SAVA

Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - SAVA Cassava Sciences, Inc. Sued for Securities Law Violations...

SAVA Deadline: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit

SAVA Deadline: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit SAVA Deadline: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud...

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Cassava Sciences Inc

Buying for a long-term investment

Buying for a short-term trade

Trading around the volatility

Avoiding it

$KLAR IPO day is upon us, how are you playing it?

Stocktwits

 IPO day is upon us, how are you playing it?

Current Price	$2.11
Prev Close	$2.18
Open	$2.16
Dividend Yield	0.00%
50-Day Moving Average	$2.21
Beta	0.96
Avg. Volume	712,366.14
PE Ratio	-0.85

52-Week High	$33.98
52-Week Low	$1.15
Market Capitalization	$105.31M
EPS (Annual)	-$1.46
Price to Book	1.20
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

SAVA
Cassava Sciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SAVA News

SAVA Cassava Sciences Inc